

**NANOPARTICLES FOR DRUG DELIVERY**

5 This application claims the benefit of U.S. Provisional Application No. 60/516,324, filed October 31, 2003, the contents of which are hereby incorporated by reference.

10 Throughout this application various publications are referenced in parenthesis. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.

15

**Background of the Invention**

Protein and peptide drugs are becoming more common as the fruits of biotechnology become available. Such drugs suffer from the necessity of delivering them by injection. Oral delivery is precluded by both the lack of oral bioavailability and by the efficient degradation of such molecules by the enzymatic systems of the gastrointestinal (GI) tract. Peptides and proteins are large, usually hydrophilic, molecules.

20 Hydrophilic molecules are poorly absorbed by passive diffusion. The cell walls of the intestine are permeable to hydrophobic molecules but not to hydrophilic molecules. The junctions between the cells are closed tightly (therefore they are called the "tight junctions") and are permeable only to

25 relatively small hydrophilic molecules. The ileal region of the small intestine has certain specialized cells (M cells and Peyer's patches) that allow entry of large molecules. However, these cells are more efficient at ingesting particles than solutions. Another part of the oral-gastrointestinal

30

tract is the sublingual region of the oral cavity. Sublingual absorption of drugs in solution is found for hydrophobic drugs such as nitroglycerin but the sublingual membranes are not permeable to hydrophilic compounds.

5

The problem of oral delivery for protein and peptide drugs has been addressed by many research groups. One offered solution is the use of microemulsions and/or of nanoparticles. Microemulsions are defined as emulsions of oil in water  
10 wherein the average particle size of the oil droplet is in the low hundreds of nanometers range (e.g. <200 nm). Microemulsions can be formed by emulsifying oil in water with surfactants with a proper input of energy such as high speed stirring, ultrasound irradiation or high pressure filtration.  
15 Some oil or wax formulations with nonionic surfactants spontaneously form microemulsions when gently mixed with water. Microemulsions may incorporate relatively hydrophobic peptides or proteins and offer a way of delivering them. When the peptide is incorporated within the oil droplet it should  
20 be protected, at least partially, from enzymatic degradation.

However, microemulsions cannot be a general method for delivering peptide drugs for several reasons. Most peptides are hydrophilic and will not be incorporated into the oil  
25 droplets of the emulsion but rather will reside in the water phase. Thus, the peptide or protein will not be protected against degradation. Also, emulsion droplets (water phase) do not offer any particular mechanism for the drug to be absorbed into the lumen of the GI tract, and the droplets in an  
30 emulsion tend to be labile, changing in size etc. as droplets merge and split up.

Nanoparticles can be made by incorporating a solute, usually a polymer, within the oil phase of a microemulsion of solvent in

water. By using double emulsion techniques (water/oil/water) one can incorporate hydrophilic molecules, such as most peptides, within the nanoparticle. Removal of the solvent by evaporation or extraction leaves the peptide incorporated in the nanoparticle. Peptides incorporated within such nanoparticles have been shown to be protected against enzymatic degradation (Lowe, P.J., Temple, C.S., *Calcitonin and Insulin in isobutylcyanoacrylate Nanocapsules: Protection against Proteases and Effect on Intestinal Absorption in Rats*, J. Pharm. Pharmacol. (1994) **46**(7), 547-552; Almeida, A.J., Runge, S., Muller, R.H., *Peptide-loaded Solid Lipid Nanospheres*, Int. J. Pharm. (1997), **149**(2), 255-265) and may be available for delivery through Peyer's patches and the like. However, such nanoparticles tend to be of relatively slow releasing nature. This property has been used as an advantage for injectable depots but may be a detriment to the availability of the drug when delivered orally. Peptides have also been incorporated among hydrophilic chains of polymers coated on a hydrophobic nanoparticle (Sakuma, S., et. al., *Stabilization of Salmon Calcitonin by Polystyrene nanoparticles having Surface Hydrophilic polymeric Chains, Against Enzymatic Degradation*, Int. J. Pharm. (1997), **159**(2), 181-189).

An elegant method for forming nanoparticles has been developed by Mumper and co-workers who take wax/surfactant mixtures that form spontaneous microemulsions when in the melt state at above 50°C and then cool to room temperature to form nanoparticles. Radionucleotides (Oyewumi, M. O., Mumper, R. J., *Engineering Tumor Targeted Gadolinium Hexanedione Nanoparticles for Potential Application in Neutron Capture Therapy*, Bioconjug. Chem. (2002), **13**(6), 1328-35; Oyewumi, M.O., Mumper, R. J., *Gadolinium Loaded Nanoparticles Engineered from Microemulsion Templates*, Drug Dev. Ind. Pharm. (2002),

28(3), 317-28) have been incorporated into the nanoparticles. In addition, by incorporating the cationic surfactant cetyltrimethylammonium bromide into the molten microemulsion and subsequent solidifying to nanoparticles they were able to  
5 bind DNA to the outside of the nanoparticles (Cui, Z., Mumper, R.J., *Genetic Immunization using Nanoparticles Engineered from Microemulsion Precursors*, Pharm. Res. (2002), 19(7), 939-46) and were able to bind cationized proteins (proteins specially treated to add cationic groups to the protein surface) when  
10 using the anionic surfactant sodium lauryl sulfate (Cui, Z. , Mumper, R. J., *Coating of Cationized Protein on Engineered Nanoparticles Results in Enhanced Immune Responses*, Int. J. Pharm., (2002), 238(1-2), 229-39). The protein was cationized to make the protein bind to the surface of the anionic  
15 nanoparticle by electrostatic forces. There is no indication that this method would work for non-cationized proteins and surely not for peptides that are shorter than proteins. Mumper's work, directed towards immunization, also implies that the proteins or DNA so attached to the outside of the  
20 particle are available for recognition and, similarly, available for degradation.

While investigating this mode of binding to charged nanoparticles formed from the cooling of microemulsions  
25 spontaneously formed above room temperature we have surprisingly found that nanoparticles formed from microemulsions that incorporate charged surface active agents are capable of binding non modified peptides to their surface. Further, while the down side of such a system was expected to  
30 be a lack of protection of the drug from degradative processes, we have also surprisingly found that the interaction with the nanoparticles also confers stability on the peptide towards enzymatic degradation while maintaining drug presentation. This phenomenon should be helpful for all

forms of delivery of the peptide whether through the ileum, intra venous, subcutaneous, intra-arterial or intramuscular injections. We have further surprisingly found that small diameter nanoparticles of this nature can be absorbed through  
5 the sublingual membrane offering another mode of drug delivery.

**Summary of the Invention**

This invention provides a pharmaceutical composition comprising a nanoparticle and any one of a peptide, a polysaccharide, or a glycoprotein, attached electrostatically thereto, and a pharmaceutically acceptable carrier.

An embodiment of the invention is a pharmaceutical composition comprising nanoparticles of i) an admixture of mono-, di-, and tri-glycerides with free polyethylene glycol and with mono-, and di-fatty acid esters of polyethylene glycol, ii) sodium docusate, and iii) glatiramer acetate.

Also provided is a process for preparing the pharmaceutical compositions described comprising i) forming a spontaneous microemulsion by heating to above 50°C a mixture of water, and a wax; ii) cooling the microemulsion to room temperature to form nanoparticles; and iii) contacting the nanoparticles with the peptide, the polysaccharide, or the glycoprotein to form the pharmaceutical composition.

Also provided by this invention is a method of delivering to a subject a peptide, a polysaccharide, or a glycoprotein, comprising administering to the subject the pharmaceutical composition described here. The administration may be sublingual, orally to the stomach, orally to the small intestine, orally to the large intestine, intramuscular, subcutaneous, intra-arterial or intravenous.

Thus, also provided herein is a general method of inhibiting enzymatic degradation of a peptide, a polysaccharide, or a glycoprotein upon oral ingestion of the peptide, the polysaccharide, or the glycoprotein by an animal, comprising electrostatically attaching the peptide, the polysaccharide,

or the glycoprotein to a nanoparticle prior to the oral ingestion, so as to thereby inhibit enzymatic degradation of the peptide, the polysaccharide, or the glycoprotein upon oral ingestion.

5

Yet furthermore, this invention provides a method of delivering to a subject a deoxyribonucleic acid molecule or a ribonucleic acid molecule, comprising administering to the subject a pharmaceutical composition comprising the  
10 deoxyribonucleic acid molecule or the ribonucleic acid molecule attached electrostatically to a nanoparticle, and a pharmaceutically acceptable carrier, wherein the administration is oral or sublingual. In this method the nanoparticle may comprises an organic wax having a melting  
15 point from 40°C to 60°C, as described previously. However, if any ionic surfactant is present, it is a cationic surfactant, such as, for example, cetyltrimethylammonium bromide, chlorhexidine salts, hexadecyl triammonium bromide, dodecyl ammonium chloride or an alkylpyridinium salt.

20

**Brief Description of the Figures**

Figure 1. Daily mean scores of each treatment group in the rat Experimental autoimmune encephalomyelitis (EAE) Model.

5

Figure 2. Kinetics of IL-2 secretion from spleen cells of mice orally treated with glatiramer acetate reference standard (GA RS) and glatiramer acetate (GA) formulations 3, 6 and 10 days of feeding.

10

Figure 3. Kinetics of TGF-beta secretion from spleen cells of mice orally treated with GA RS and GA formulations 3, 6 and 10 days of feeding.



### Detailed Description of the Invention

This invention provides a pharmaceutical composition comprising a nanoparticle and any one of a peptide, a polysaccharide, or a glycoprotein, attached electrostatically thereto, and a pharmaceutically acceptable carrier.

The nanoparticle may comprise an organic wax having a melting point from 40°C to 60°C. The organic wax may be stearic acid; atomized glyceryl palmitostearate; atomized glyceryl behenate; a paraffin wax having a melting point from 40° C to 60° C; a mixture of mono-, di-, and tri-glycerides obtained by esterification of fatty acids of natural origin with glycerol and having a melting point from 40° C to 60° C; a mixture of mono-, di-, and tri-glycerides obtained by transesterification of fatty acids of natural origin and having a melting point from 40° C to 60° C; or a mixture of mono-, di-, and tri-glycerides of C12-C18 fatty acids and having a melting point from 40° C to 60° C.

The organic wax may be admixed with a nonionic surfactant. The admixture of organic wax and non-ionic surfactant may be cetyl alcohol with polysorbate 60, polyoxyl 2 stearyl ether with polysorbate 80, or mono-, di-, and tri-glycerides with free polyethylene glycol and with mono-, and di-fatty acid esters of polyethylene glycol.

The nanoparticle can comprise an ionic surface-active agent. The surface-active agent may have a charged head and a hydrophobic tail, and can be an anionic surfactant, such as, for example, sodium lauryl sulfate, sodium cholate, sodium taurocholate, or sodium docusate. In one embodiment, the surface-active agent is sodium docusate.

In one embodiment, the peptide, the polysaccharide, or the glycoprotein has a net positive charge and the nanoparticle has a net negative charge, such that the peptide, the polysaccharide, or the glycoprotein is electrostatically  
5 attached to the nanoparticle. In such an embodiment, the peptide attached to the nanoparticle may have more combined total lysine plus arginine groups than the combined total of aspartic acid plus glutamic acid groups. In such an embodiment, the peptide may be glatiramer acetate or an  
10 interferon; and the polysaccharide may be gentamycin, amikacin or tobramycin.

In another embodiment, the surface-active agent may be a cationic surfactant, such as, for example,  
15 cetyltrimethylammonium bromide, chlorhexidine salts, hexadecyl triammonium bromide, dodecyl ammonium chloride or an alkylpyridinium salt.

In an embodiment, the peptide, the polysaccharide, or the glycoprotein may have a net negative charge and the nanoparticle has a net positive charge, such that the peptide, the polysaccharide, or the glycoprotein is electrostatically  
20 attached to the nanoparticle. In such an embodiment, the peptide attached to the nanoparticle can has more combined total aspartic acid plus glutamic acid groups than lysine plus arginine groups. In such an embodiment, the polysaccharide  
25 attached to the nanoparticle may be heparin.

In any embodiment of the invention, the pharmaceutical  
30 composition may be characterized in that the rate of enzymatic degradation of the peptide, the polysaccharide, or the glycoprotein when electrostatically attached to the nanoparticle is lower than the rate of enzymatic degradation

of the peptide, the polysaccharide, or the glycoprotein when unattached to the nanoparticle in solution.

Yet a further embodiment of the invention is a pharmaceutical composition comprising nanoparticles of i) an admixture of mono-, di-, and tri-glycerides with free polyethylene glycol and with mono-, and di-fatty acid esters of polyethylene glycol, ii) sodium docusate, and iii) glatiramer acetate.

10 In this embodiment, the admixture may comprise 60-90% by weight of the composition, wherein the sodium docusate comprises 2-30% by weight of the composition, and wherein the glatiramer acetate comprises 3-20% of the composition. Alternatively, in this embodiment, the admixture may comprise 15 80-85% by weight of the composition, wherein the sodium docusate comprises 5-7% by weight of the composition, and wherein the glatiramer acetate comprises 8-15% of the composition.

20 The admixture may comprise 20% mono-, di-, and tri-glycerides, 8% free polyethylene glycol, and 72% mono-, and di-fatty acid esters of polyethylene glycol.

In any of the embodiments of this invention, the pharmaceutical composition may be characterized in that the rate of enzymatic degradation of the glatiramer acetate when electrostatically attached to the nanoparticle is lower than the rate of enzymatic degradation of the glatiramer acetate when unattached to the nanoparticle in solution.

30

In any of the embodiments of this invention, the nanoparticle can have an average diameter of between 1 nm and 5000 nm. In certain embodiments, the nanoparticle has an average diameter of between 200 nm and 3000 nm; or an average diameter of

between 500 nm and 2000 nm; or an average diameter of between 1 nm and 1000 nm; or an average diameter of between 1 nm and 500 nm; or an average diameter of between 10 nm and 300 nm; or an average diameter of between 20 nm and 200 nm; or an average diameter of between 20 nm and 150 nm; or an average diameter of between 100 nm and 600 nm; or an average diameter of between 200 nm and 500 nm.

Another embodiment of this invention is a lyophilized pharmaceutical composition of any composition described here.

Also provided is a process for preparing the pharmaceutical compositions described comprising i) forming a spontaneous microemulsion by heating to above 50°C a mixture of water, and a wax; ii) cooling the microemulsion to room temperature to form nanoparticles; and iii) contacting the nanoparticles with the peptide, the polysaccharide, or the glycoprotein to form the pharmaceutical composition.

In the process, the wax may be an organic wax having a melting point from 40°C to 60°C, such as, for example, stearic acid; atomized glyceryl palmitostearate; atomized glyceryl behenate; paraffin waxes having a melting point from 40° C to 60° C; a mixture of mono-, di-, and tri-glycerides obtained by esterification of fatty acids of natural origin with glycerol and having a melting point from 40° C to 60° C; a mixture of mono-, di-, and tri-glycerides obtained by transesterification of fatty acids of natural origin and having a melting point from 40° C to 60° C; or a mixture of mono-, di-, and tri-glycerides of C12-C18 fatty acids and having a melting point from 40° C to 60° C.

As in the composition, in the process, the wax may comprise a nonionic surfactant, or an ionic surfactant. The wax with

non-ionic surfactant may be cetyl alcohol with polysorbate 60, polyoxyl 2 stearyl ether with polysorbate 80, or mono-, di-, and tri-glycerides with free polyethylene glycol and with mono-, and di-fatty acid esters of polyethylene glycol.

5

The ionic surfactant may be an anionic surfactant, such as, for example, sodium lauryl sulfate, sodium cholate, sodium taurocholate, or sodium docusate.

10 The ionic surfactant may also be a cationic surfactant, such as, for example, cetyltrimethylammonium bromide, chlorhexidine salts, hexadecyl triammonium bromide, dodecyl ammonium chloride or an alkylpyridinium salt.

15 In the process, the peptide, the polysaccharide, or the glycoprotein are as described for the composition.

Also provided by this invention is a method of delivering to a subject a peptide, a polysaccharide, or a glycoprotein,  
20 comprising administering to the subject the pharmaceutical composition described here. The administration may be sublingual, orally to the stomach, orally to the small intestine, orally to the large intestine, intramuscular, subcutaneous, intra-arterial or intravenous.

25

Also provided herein is a general method of inhibiting enzymatic degradation of a peptide, a polysaccharide, or a glycoprotein upon oral ingestion of the peptide, the polysaccharide, or the glycoprotein by an animal, comprising  
30 electrostatically attaching the peptide, the polysaccharide, or the glycoprotein to a nanoparticle prior to the oral ingestion, so as to thereby inhibit enzymatic degradation of the peptide, the polysaccharide, or the glycoprotein upon oral ingestion. The nanoparticle composition, its formation and

attachment to the peptide, the polysaccharide and the glycoprotein are as described herein. For example, in one embodiment, the peptide may be glatiramer acetate; in another embodiment, the nanoparticle may comprise i) an admixture of  
5 mono-, di-, and tri-glycerides with free polyethylene glycol and with mono- and di-fatty acid esters of polyethylene glycol, and ii) sodium docusate; and the peptide, the polysaccharide, or the glycoprotein may be attached to the nanoparticle by i) forming a spontaneous microemulsion by  
10 heating to above 50°C a mixture of water, and a wax; ii) cooling the microemulsion to room temperature to form nanoparticles; and iii) contacting the nanoparticles with the peptide, the polysaccharide, or the glycoprotein, thereby electrostatically attaching the peptide, the polysaccharide,  
15 or the glycoprotein to the nanoparticle.

Yet furthermore, this invention provides a method of delivering to a subject a deoxyribonucleic acid molecule or a ribonucleic acid molecule, comprising administering to the  
20 subject a pharmaceutical composition comprising the deoxyribonucleic acid molecule or the ribonucleic acid molecule attached electrostatically to a nanoparticle, and a pharmaceutically acceptable carrier, wherein the administration is oral or sublingual. In this method the  
25 nanoparticle may comprises an organic wax having a melting point from 40°C to 60°C, as described previously. However, if any ionic surfactant is present, it is a cationic surfactant, such as, for example, cetyltrimethylammonium bromide, chlorhexidine salts, hexadecyl triammonium bromide, dodecyl  
30 ammonium chloride or an alkylpyridinium salt.

The subject invention provides a pharmaceutical composition prepared by any one of the disclosed processes.

The subject invention also provides any one of the disclosed pharmaceutical compositions comprising glatiramer acetate in  
5 an amount effective to treat an autoimmune disease or an inflammatory non-autoimmune disease in a subject, and a pharmaceutically acceptable carrier.

In one embodiment, the autoimmune disease is multiple  
10 sclerosis.

The subject invention also provides a method for treating a subject afflicted with an autoimmune disease or an inflammatory non-autoimmune disease, which comprises  
15 administering to the subject any of the disclosed pharmaceutical compositions.

In another embodiment, the administration is through intravenous, intraperitoneal, intramuscular, subcutaneous,  
20 oral, intranasal, buccal, vaginal, rectal, intraocular, intrathecal, topical, sublingual or intradermal routes.

In a further embodiment, the administration is oral.

25 The subject invention further provides a method of treating a subject afflicted with relapsing remitting multiple sclerosis which comprises oral administration of a nanoparticulate formulation of glatiramer acetate, wherein the amount of glatiramer acetate in the nanoparticulate formulation is  
30 effective to alleviate a symptom of the relapsing-remitting multiple sclerosis in the subject.

The subject application also provides for the use of any one of the disclosed pharmaceutical compositions comprising glatiramer acetate for the treatment of an autoimmune disease.

- 5 In a further embodiment, the use of any one of the disclosed pharmaceutical compositions for the treatment of multiple sclerosis.

In another embodiment, the use of any one of the disclosed  
10 pharmaceutical compositions for use as a medicament.

The subject application further provides for the use of any one of the disclosed pharmaceutical compositions comprising glatiramer acetate in the manufacture of a medicament for the  
15 treatment of an inflammatory non-autoimmune disease.

In another embodiment, any one of the disclosed pharmaceutical compositions is formulated for intravenous, intraperitoneal, intramuscular, subcutaneous, oral, intranasal, buccal,  
20 vaginal, rectal, intraocular, intrathecal, topical, sublingual or intradermal administration.

In still another embodiment, any one of the disclosed pharmaceutical compositions is formulated for oral  
25 administration.

In an embodiment, any one of the disclosed medicaments is formulated for intravenous, intraperitoneal, intramuscular, subcutaneous, oral, intranasal, buccal, vaginal, rectal,  
30 intraocular, intrathecal, topical, sublingual or intradermal administration.

In another embodiment, any one of the disclosed medicaments is formulated for oral administration.



The subject application further provides for the use of a nanoparticulate formulation of glatiramer acetate in the treatment of the relapsing-remitting multiple sclerosis.

5

The subject application also provides for the use of a nanoparticulate formulation of glatiramer acetate in a medicament.

## 10 Definitions

The term "nanoparticle" as used in this document refers to a particle having an average size of 1-5000 nanometers (nm). The chemical composition of the nanoparticle can vary as described throughout this document.

15

The terms "peptide" as used in this document refers to a peptide or a protein whose net electric charge, if any, is due solely to its composition of naturally occurring amino acids, and whose net electric charge has not been modified by the covalent addition of a non-amino acid molecule. The term "peptide" as used in this document includes within its definition a protein.

20

The term "polysaccharide" as used in this document refers to a polysaccharide whose net electric charge, if any, is due solely to its composition of naturally occurring sugars.

25

The term "glycoprotein" as used in this document refers to a glycoprotein whose net electric charge, if any, is due solely to its composition of naturally occurring amino acids and sugars.

30

## Production of Nanoparticles

Nanoparticles can be produced by milling of macro or microparticles in special mills of high energy to obtain nanoparticles. Nanoparticles can also be formed using emulsion techniques as described below. An emulsion is a meta  
5 stable mixture of two immiscible liquids in which one of the liquids has been broken up into small droplets that are dispersed in the other liquid. An oil-in-water emulsion consists of small droplets of oil dispersed in a continuous water phase. Typically, the oil droplets have a surface-  
10 active agent associated with them to give the emulsion some stability. The size of the emulsion droplets can be from the micrometer to nanometer range. An emulsion in which the droplet size is less than about 200 nm (0.2 micron) is called a microemulsion. Oil-in-water emulsions can be made from  
15 almost any non water-soluble liquid.

Nanoparticles so formed can be associated with peptide drugs or protein drugs to stabilize the drugs against degradation and to enhance the absorption of large hydrophilic peptide or  
20 protein drugs. Nanoparticles with associated peptide or protein drugs for sublingual delivery should have an average diameter of between 1 nm and 1000 nm, preferably between 10 nm and 300 nm and most preferably between 20 nm and 200 nm. Nanoparticles with associated peptide or protein for oral  
25 delivery should have an average diameter of between 1 nm and 5000 nm, preferably between 200 nm and 3000 nm and most preferably between 500 nm and 2000 nm. Nanoparticles with associated peptide or protein for subcutaneous or intramuscular delivery should have an average diameter of  
30 between 1 nm and 1000 nm, preferably between 100 nm and 600 nm and most preferably between 200 nm and 500 nm. Nanoparticles with associated peptide or protein for intra-arterial or intravenous delivery should have an average diameter of

between 1 nm and 500 nm, preferably between 10 nm and 300 nm and most preferably between 20 nm and 150 nm.

The size of the emulsion droplets can be controlled by several techniques. To obtain small droplets one may stir the oil in water mixture at very high speed or one may force the mixture to pass through a filter with very small pores by using a pressure differential. Depending upon the composition of the oil phase and the surfactants present one may obtain emulsions of almost any size droplet and with varying stability. Emulsion droplets may be used to form microparticles or nanoparticles. Solid materials that are dissolved in the oil droplets will solidify into particles of size of similar order of magnitude as the droplets upon removing the oil, which is acting as a solvent. The oil may be removed by extraction into another solvent in which the oil phase is soluble but the solute is not or by evaporation in the case of a volatile oil phase. These methods are typically used in the formation of microparticles and microspheres from polymeric materials such as polylactic-glycolic acid copolymers. The polymer material is dissolved in an organic non-water soluble solvent such as methylene chloride or ethyl acetate, an emulsion of the organic solution is made in the water phase (usually with a surfactant such as polyvinyl alcohol added) and the organic solvent is removed either by evaporation or by extraction leaving behind a suspension of microparticles or microspheres in the water phase. If a drug was included in the organic phase before the emulsification step then one obtains microspheres or microparticles containing a drug. If the emulsion was formed with small enough droplets then the size of the particles can be brought down into the nanometer range.

An alternate way of making micro or nanoparticles is to use an organic wax that is liquid above room temperature and solid at

room temperature as the oil phase. A drug can be dissolved in the wax phase and the wax emulsified above room temperature. Upon cooling, one obtains a suspension of microparticles or nanoparticles of about the same size as the oil droplets in the emulsion without the need to extract or evaporate a solvent. Microparticles or nanoparticles of this sort are best suited for the delivery of oil soluble drugs and are best for forming long term delivery depots. The drug is embedded in an organic polymer or wax and is not immediately available for delivery until it can diffuse out of the matrix. Typically the diffusion takes place only after degradation of the particle matrix. Water-soluble drugs can be loaded into microparticles of this sort too, but in general with low drug loading and low efficiency. Since the water-soluble drug is not soluble in the oil phase, one needs to first make a water-in-oil emulsion which is then used to make the oil in water emulsion giving a water-in-oil in water double emulsion. For peptide and protein drugs where the solubility in water is not very high either, this drastically limits the amount of drug that can be incorporated into the system. Moreover, the drug is embedded within a non water-soluble matrix making it unavailable for immediate release as mentioned.

An improved system of nanoparticles or microparticles for more immediate use would have the peptide or protein drug attached to the microparticle or nanoparticle on the outer surface. Nanoparticles should be particularly useful for such a delivery system since their surface area per unit weight is great, allowing significant loading of drug. The down side of such a system was expected to be the lack of protection of the drug from degradative processes. We have surprisingly found, that when making nanoparticles from waxes that have surface active agents embedded in them and electrostatically binding a

charged peptide or protein to the surface, the peptide is both available for delivery and protected against degradation.

In order to bond peptide or protein drugs to the surface of nanoparticles, the nanoparticle needs to be produced with a charged surface. This can be accomplished by making the nanoparticle from a polymer that contains ionic groups or by adding the charge by blending a charged molecule into the material making up the nanoparticle. In one embodiment of the invention waxes with melting points between 40 and 60 degrees are used. The waxes are melted and an ionic surfactant molecule is dissolved in the wax. The wax is then emulsified with warm (50-70 degrees Centigrade) water with the optional use of a non-ionic surfactant in the emulsification step. Suitable waxes for use in such a system are Witepsol® E85, microcrystalline wax, Stearic Acid, Compritol® 888 ATO, and Precirol® ATO 5 with Compritol® 888 ATO being a more preferable choice. Suitable anionic surfactant for such systems are sodium lauryl sulfate, sodium cholate, sodium taurocholate, and sodium ducosate with the ducosate being most preferred. When using sodium ducosate as the surface active agent it can be added in amounts between 1% and 30%, more preferably about 5% to 10% and most preferably around 7% by weight when compared to the wax.

25

The size of the molten wax droplets in the warm emulsion is controlled by the speed of the high shear mixer used to homogenize the mixture and can be determined by experimentation. The higher the speed and the longer the molten wax is homogenized in the water phase, the smaller the droplets will be. After the homogenization is complete, the mixture is cooled to below the solidification point of the wax. The nanoparticles thus formed have an embedded hydrophobic tail of the surfactant within them, thus

immobilizing the surfactant with its charged head on the surface interacting with the aqueous phase.

Proteins or peptide drugs with a net positive charge can be  
5 attached electrostatically to the charged nanoparticles by  
mixing an aqueous solution of the peptide or protein with a  
suspension of the nanoparticles or microparticles. Examples of  
such proteins and peptides are glatiramer acetate, protamine  
sulfate, cationic antimicrobial peptides such as crecropins,  
10 magainin, dipterocins, defensins, and gambicin, polylysine,  
polyarginine, and other peptides or proteins that have an  
excess total lysine plus arginine groups when compared to  
total aspartic acid plus glutamic acid groups. Cationic  
saccharide drugs such as gentamycin, amikacin and tobramycin  
15 can be used in place of the peptide or protein molecules.  
Glatiramer acetate is the most preferred embodiment.

The nano-suspension thus formed of peptide attached to the  
nanoparticles can be lyophilized to a powder for long-term  
20 storage. The lyophilized powder can be reconstituted in buffer  
to re-obtain the nano-suspension of drug. Nano-suspensions of  
attached drug thus obtained are particularly suited for oral  
delivery. If made with an average diameter below 200 nm the  
nano-suspension is suitable for sublingual delivery since  
25 nanoparticles can transverse the sublingual membrane. For oral  
delivery to the gastrointestinal tract larger nanoparticles  
are most preferred since they are the size most readily  
recognized by the Peyer's patches and M-cells. For such oral  
delivery the nano-suspension, as a lyophilized powder or as a  
30 reconstituted suspension, is to be delivered to the small  
intestine by using an enteric coated capsule. The enhanced  
stability of the peptide or protein when attached in the nano-  
suspension formulation allows for more time for the peptide

drug to be absorbed in the intestine before it is degraded by enzymes in the gastrointestinal tract.

For bonding proteins and peptides with residual negative  
5 charge one needs to use a surface active agent in the preparation that has a cationic head group. Examples of such molecules are cetyltrimethylammonium bromide, chlorhexidine salts, hexadecyl triammonium bromide, dodecyl ammonium chloride and alkylpyridinium salts. The procedure for their  
10 formation is the same as when using surfactants with anionic charged heads. Examples of peptides and proteins with net negative charge are anionic anti microbial peptides such as enkelytin, peptide B, and dermicidin, polyaspartic acid, polyglutamic acid, and any peptide or protein that has a net  
15 excess of aspartic acid plus glutamic acid groups when compared to lysine plus arginine groups. Negatively charged polysaccharide drugs such as heparin or nucleic acid oligomers or polymers such as DNA or RNA and their fragments and antisense analogs of such, could also be used.

20

In a more preferred embodiment of this invention the wax used to form the nanoparticles is a wax formulated to spontaneously form a microemulsion. Such wax-with-surfactant formulations spontaneously form a microemulsion (droplet size less than 200  
25 nm) when mixed with water above their melting point. The surfactant in such mixtures is often of the non ionic type so that an ionic surfactant need be added to the wax/surfactant formulation melt in order to obtain charged nanoparticles upon solidification of the microemulsion. Wax surfactant  
30 formulations that are suitable for our use are those that melt above room temperature and can be emulsified as a liquid in warm to hot water. Examples of such wax surfactant formulations are "emulsifying wax" which is a mixture of cetyl alcohol and polysorbate 60 in a molar ratio of about

20:1, polyoxyl 2 stearyl ether (Brij 72) and Tween 80 mixtures, and the Gelucire® series of waxes which are mixtures of 20% mono, di and tri glycerides, 72% mono and di fatty acid esters of PEG 1500 and 8% free PEG 1500. The Gelucire® series  
5 are preferred with Gelucire® 50/13 with a nominal melting point of 50°C most preferred. Melted Gelucire® 50/13 spontaneously forms a clear microemulsion when mixed with water. In order to make the charged surface nanoparticles, it is necessary to add a charged surfactant to the wax melt to form the microemulsion  
10 with the surfactant groups incorporated. Suitable anionic surfactant for such systems are sodium lauryl sulfate, sodium cholate, sodium taurocholate, and sodium ducosate. Sodium ducosate is the most preferred surface-active agent with an anionic head. When using sodium ducosate as the surface active  
15 agent can be added in amounts between 1% and 30%, more preferably about 5% to 10% and most preferably around 7% by weight when compared to the wax formulation.

Proteins or peptide drugs with a net positive charge can be  
20 attached electrostatically to the charged nanoparticles thus formed by mixing an aqueous solution of the peptide or protein with a suspension of the nanoparticles or microparticles. Examples of such proteins and peptides are glatiramer acetate, protamine sulfate, cationic antimicrobial peptides such as  
25 crecropins, magainin, diptericins, defensins, and gambicin, polylysine, polyarginine, and other peptides or proteins that have an excess total lysine plus arginine groups when compared to total aspartic acid plus glutamic acid groups. Cationic saccharide drugs such as gentamycin, amikacin and tobramycin  
30 can be used in place of the peptide or protein molecules.

The nano-suspension thus formed of bound peptide to the nanoparticles can be lyophilized to a powder for long-term storage. The lyophilized powder can be reconstituted in buffer



to re-obtain the nano-suspension of drug. Nano-suspensions of bound drug thus obtained are particularly suited for oral delivery as described above. If made with an average diameter below 200 nm the nano suspension is suitable for sublingual  
5 delivery since nanoparticles can transverse the sublingual membrane. These nano suspensions can also be used for oral delivery to the gastrointestinal tract for absorption through Peyer's patches and M-cells. For such oral delivery the nano-suspension, as a lyophilized powder or as a reconstituted  
10 suspension, is to be delivered to the small intestine by using an enteric coated capsule. The enhanced stability of the peptide or protein when bound in the nano-suspension formulation allows for more time for the peptide drug to be absorbed in the intestine before it is degraded by enzymes in  
15 the gastrointestinal tract.

In an embodiment 60 - 90% w/w Gelucire® 50/13 is used as the self emulsifying wax, 2 - 30% w/w sodium ducosate is used as the anionic surfactant, and 3 - 20% w/w glatiramer acetate is  
20 used as the peptide drug. In a most preferred embodiment about 80 - 85% w/w Gelucire® 50/13 is used as the self emulsifying wax, 5 - 7% w/w sodium ducosate is used as the anionic surfactant, and 8-15 % w/w glatiramer acetate is used as the peptide drug. The nano suspension thus formed of bound  
25 peptide to the nanoparticles can be lyophilized to a powder for long term storage. The lyophilized powder can be reconstituted in buffer to re-obtain the nano suspension of drug.

30 Again here with the self emulsifying wax that forms a microemulsion for bonding proteins and peptides with residual negative charge one needs to use a surface active agent in the preparation that has a cationic head group. Examples of such molecules are cetyltrimethylammonium bromide, chlorhexidine

salts, hexadecyl triammonium bromide, dodecyl ammonium chloride and alkyipyridinium salts. The procedure for their formation is the same as when using surfactants with anionic charged heads. Examples of peptides and proteins with net  
5 negative charge are anionic anti microbial peptides such as enkelytin, peptide B, and dermicidin, polyaspartic acid, polyglutamic acid, and any peptide or protein that has a net excess of aspartic acid plus glutamic acid groups when compared to lysine plus arginine groups. Negatively charged  
10 polysaccharide drugs such as heparin or nucleic acid oligomers or polymers such as DNA or RNA and their fragments and antisense analogs of such, could also be used.

#### Therapeutic Uses

15 The present application contemplates that pharmaceutical compositions of nanoparticles with glatiramer acetate treat the same autoimmune diseases and inflammatory non-autoimmune diseases as glatiramer acetate (U.S. Patent Application Publication No. 20020055466 A1, published May 9, 2002  
20 (Aharoni, et al.); U.S. Patent No. 6,514,938 B1, issued February 4, 2003 to Gad, et al.; PCT International Publication No. WO 01/60392, published August 23, 2001 (Gilbert, et al.); U.S. Patent Application Publication No. 2004/0006022, published January 8, 2004 (Strominger, et al.); U.S. Patent  
25 Application Publication No. 20020077278 A1, published June 20, 2002 (Young, et al.); U.S. Patent Application Publication No. 20020037848 A1, published March 28, 2002 (Eisenbach-Schwartz) and U.S. Patent Application Publication No. 20030004099 A1, published January 2, 2003 (Eisenbach-Schwartz); PCT  
30 International Publication No. WO 01/97846, published December 27, 2001 (Moses, et al.)).

## Experimental Details

### Materials

Gelucire® 50/13 is a commercially available semi-solid  
5 bioavailability enhancer and controlled-release agent for hard  
gelatin capsule formulations. Its chemical description is:  
Stearoyl macrogol-32 glycerides. Gelucire® 50/13 is  
synthesized by an alcoholysis/esterification reaction using  
hydrogenated palm oil and PEG 1500 as starting materials.  
10 Gelucire® 50/13 is therefore a well defined mixture of mono-,  
di-, and triglycerides and mono- and di-fatty acid esters of  
polyethylene glycol 1500, and free polyethylene glycol 1500.  
The predominant fatty acid is palmitostearic acid (C16-C18).  
Gelucire® 50/13 is a waxy solid (blocks or pellets), having a  
15 faint odor, a melting range (drop point) of 46.0 to 51.0°C,  
and a hydrophile-lipophile balance value of 13. European  
Pharmacopoeia 4rd edition: conforms to the "Stearoyl  
macrogolglycerides" monograph. U.S. Drug Master File n°5253.

20 Docusate sodium, or sulfobutanediolic acid 1,4-bis-(2-  
ethylhexyl) ester sodium salt, is a pharmaceutical surfactant  
or wetting agent that has the formula  $C_{20}H_{37}NaO_7S$  and a  
molecular weight of 444.57 (The Merck Index, 12<sup>th</sup> Ed.).  
Docusate sodium is commercially available, e.g. as Colace.

25 Glatiramer acetate (GA) is one example of a peptide drug for  
which the development of an oral alternative to delivery would  
be a significant advance. GA, an acetate salt of a synthetic  
copolymer of a random mixture of four amino acids, is one of  
30 the agents approved by the FDA for treating the relapsing-  
remitting form of Multiple Sclerosis (MS) (Physician's Desk  
Reference, 56 ed. pgs 3306 - 3310). MS is a chronic disease  
of the central nervous system that is characterized by  
inflammation, demyelination, and axon loss (van Oosten, B. W.

et. al., *Choosing Drug Therapy for Multiple Sclerosis. An Update.*, Drugs, 1998, 56(4), 555-569).

Example 1

5 Gelucire<sup>®</sup> 50/13 wax (82.6 parts) was placed in a jacketed reactor fitted with a stirrer. The wax was melted by heating to about 70°C with stirring. Sodium Ducosate (5.8 parts) was added and a solution of the ducosate in the melted wax was obtained. Preheated water (784 parts) was added and the  
10 mixture stirred at 200 rpm for 15 minutes at 70 °C. A spontaneous microemulsion formed. The mass was then cooled to room temperature over a period of 120 minutes forming a nano suspension from the microemulsion. Glatiramer acetate (GA) (11.6 parts) was dissolved in 100 parts water and added to the  
15 stirred reactor. The mixture was stirred for thirty minutes allowing the GA to bind to the particles. The nano suspension was frozen at -20°C for 12 - 20 hours and then lyophilized for 72 hours. A well formed cake was obtained. The lyophilized cake was milled in a QuadroComil milling machine through 0.8  
20 mm screen to obtain a powder. The powder was reconstituted in phosphate buffer (0.05M pH = 6.8) to obtain the drug nano suspension.

The particle size distribution of the nano suspension was  
25 measured using a Mastersizer2000, (Malvern Instruments Ltd., detection range 0.02-2000um) by dispersing the particles in cold (14 - 20 °C) water. Results of the measurements were as follows:

d(0.1) = 76 +/- 5 nm  
30 d(0.5) = 124 +/- 8 nm  
d(0.9) = 224 +/- 4 nm

(Ten percent by volume [or weight] of the particles have a diameter less than 76 nm, 50% by volume [or weight] have a

diameter less than 124 nm and 90% by volume [or weight] of the particles have a diameter of less than 224 nm).

The percent of the GA that is bound to the nanoparticles was  
5 determined by separating the free GA from the bound on a  
Sephadex column. The nanoparticles appear in the first  
fractions which correspond to the void volume of the column,  
while the free GA appears in later fractions after being  
retained on the column. To accomplish this separation, 25 mg  
10 of the reconstituted nanoparticles were loaded on a Sephadex  
G-75 column (10 x 200 mm) and eluted with water at a flow rate  
of 0.5 ml/min. Fractions of 5 ml each were collected.  
Following the separation by UV absorption at 275 nm indicated  
that there were two peaks of material, one at the void volume  
15 corresponding to the first 7 fractions of the eluate and the  
other in subsequent fractions. The two peaks were well  
separated. The amount of GA in each fraction was determined  
by an HPLC analysis on a Superose 12 HR 10/30 column  
(Pharmacia, 10 x 30 mm) using an acidic phosphate buffer (0.1  
20 M, pH= 1.5) at a flow of 0.5 ml/min and using UV detection at  
208 nm. The acidic buffer removes the GA from the particles  
and allows the determination of total GA in the fraction. The  
percent of GA bound in the sample was the ratio of the total  
amount of GA determined in the fractions corresponding to the  
25 void volume peak, to the total amount of GA determined in all  
the fractions multiplied by 100. The percent bound was found  
to be 50 +/- 5 % (w/w).

#### Example 2

30 Gelucire<sup>®</sup> 50/13 wax (72.2 parts) was placed in a jacketed  
reactor fitted with a stirrer. The wax was melted by heating  
to about 70°C with stirring. Sodium Ducosate (5.4 parts) was  
added and a solution of the ducosate in the melted wax was  
obtained. Preheated water (684 parts) was added and the

mixture stirred at 200 rpm for 15 minutes at 70 °C. A spontaneous microemulsion forms. The mass was then cooled to room temperature over a period of 120 minutes forming a nano suspension from the microemulsion. Glatiramer acetate (GA) (10.9 parts) was dissolved in 100 parts water and added to the stirred reactor. The mixture was stirred for thirty minutes allowing the GA to bind to the particles. Polyvinylpyrrolidone (PVP k30, 11.5 parts) was dissolved in 100 parts water and added to the nano suspension. The nano suspension was frozen at -20°C for 12 - 20 hours and then lyophilized for 72 hours. A well formed cake was obtained. The lyophilized cake was milled in a Quadro Comil milling machine through 0.8 mm screen to obtain a powder. The powder was reconstituted in phosphate buffer (0.05M pH = 6.8) to obtain the drug nano suspension.

The particle size distribution was measured as in Example 1 and found to be very similar i.e.

$d(0.1) = 79 \pm 2 \text{ nm}$

$d(0.5) = 121 \pm 1 \text{ nm}$

$d(0.9) = 250 \pm 16 \text{ nm}$

and the percent bound was determined as in Example 1 but with the UV detection in the GA content analysis being at 280 nm and found to be 50  $\pm$  5 % (w/w) as before.

### Example 3 - Protection from Enzymatic degradation

The enzymatic degradation of free GA in solution versus GA in the nano suspension (~50% bound to the nanoparticles) and versus GA bound to the nanoparticles (~100% bound) was studied using pancreatin. The GA bound to the nanoparticles was prepared by collecting fractions from the void volume of the Sephadex column as described in Example 1 and pooling the samples. Pancreatin is a mixture of pancreatic proteases consisting of trypsin and chymotrypsins.

Pancreatin 3.5 mg was dissolved in 10 ml of 0.05M phosphate buffer pH= 6.8. Free GA, GA in nano suspension, or fully bound GA, 35 mg as GA, was dissolved or suspended in 10 ml of 0.05M phosphate buffer pH=6.8. 1 ml of the pancreatin solution and 1 ml of the GA solution or suspension were mixed (the ratio of pancreatin to GA was fixed at 1:10) and held at 37 °C. At fixed time points the enzymatic reaction was stopped by adding 0.4 ml of 1N HCl. The residual GA content of the mixture was determined by the HPLC method described in Example 1. The results of the percent residual GA at various time points is given in the table 1.

Table 1

Time [min]	Free GA	Nano suspension (-50% bound to particles)	Nano suspension (-50% bound to particles)+PVP	Nanoparticle Bound GA only (-100% bound)
0	100.0 +/-0.0	100.0 +/-0.0	100.0	100.0
1	75.1 +/-3.9	87.7 +/-4.1	90.4	98.8
2	63.4 +/-4.8	83.0 +/-2.8	81.2	94.9
3	56.3 +/-4.7	80.8 +/-4.1	78.6	91.2
6	47.1 +/-4.4	74.6 +/-7.3		80.0
10		66.5 +/-5.9		74.5
15		56.4 +/-4.0		

After three minutes there was 56% of the free GA remaining while the nano suspension showed 81% remaining. The fully bound GA showed 91% remaining. The nano suspension showed 56% remaining after 15 minutes or 5 times as long as the free GA. The enhanced stability of the GA in the nano suspension formulation should aid in its ability to be absorbed in various parts of the gastrointestinal tract.

GA has been shown to significantly reduce the relapse rate of multiple sclerosis and to significantly reduce the burden of

disease lesions as seen in magnetic resonance imaging measures (Simpson, D. et. al. *Glatiramer Acetate: a Review of its use in Relapsing-Relmitting Multiple Sclerosis*, CNS- Drugs, 2002, 16(12), 825-850). GA is an acetate salt of a synthetic  
5 copolymer of a random mixture of four amino acids (Physician's Desk Reference, 56 ed. pgs 3306 - 3310) and while its mechanism of action has not been totally elucidated, it is believed to down-regulate pro-inflammatory cytokines, up-regulate anti-inflammatory cytokines, and to interfere with  
10 antigen presentation (Zhang, J. et. al., *A Comparison of Action of Interferon beta and Glatiramer Acetate in the Treatment of Multiple Sclerosis*, Clin. Ther. 2002, 24(12), 1998-2021; Miller, A. et. al. *Treatment of Multiple Sclerosis with Copolymer-1 (Copaxone): Implicating Mechanisms of Th1 to*  
15 *Th2/Th3 Immune Deviation*, J. Neurimmunol., 1998, 92(1-2), 113-121; Ragheb, S. et. al. , *Long-Term Therapy with Glatiramer Acetate in Multiple Sclerosis: Effect on T-cells*, Mult. Scler. 2001, 7(1), 43-47; Hussien, Y et. al., *Glatiramer Acetate and IFN-beta Act on Dendritic Cells in Multiple*  
20 *Sclerosis*, J. Neuroimmunol., 2001, 121(1-2), 102-110) leading to less destruction of axonal myelin. GA, administered as a 20 mg subcutaneous daily injection, has shown extended clinical benefits (Simpson, D. et. al. *Glatiramer Acetate: a Review of its use in Relapsing-Relmitting Multiple Sclerosis*, CNS- Drugs,  
25 (2002), 16(12), 825-850; Johnson, K. P., et. al., *Sustained Clinical Benefits of Glatiramer Acetate in Relapsing Multiple Sclerosis patients Observed for Six Years. Copolymer-1 Multiple Sclerosis Study Group*, Mult. Scler. (2000), 6(4), 255-266) for MS patients. GA has a more benign side effect  
30 profile than other immunomodulatory agents that are approved for use and is very well tolerated (Simpson, D. et. al. *Glatiramer Acetate: a Review of its use in Relapsing-Relmitting Multiple Sclerosis*, CNS- Drugs, (2002), 16(12), 825-850; Francis, D.A., *Glatiramer Acetate*, Int. J. Clin. Pract. 2001,



55(6), 394-398). GA, as well as the other agents, are protein or peptide drugs and are administered by injection only. The development of an oral alternative to delivery of this drug is a significant improvement in therapy due to patient  
5 convenience and preference.

To solve the problem of oral delivery of peptide and protein drugs to a human it was necessary to find methods that can stabilize the drug against degradation in the gastrointestinal  
10 tract and at the same time enhance the absorption of the large hydrophilic molecules. We have surprisingly found that nanoparticles with a surface attached peptide or protein drug can carry out both of these functions.

15

Example 4 - Efficacy in Rat Experimental Autoimmune Encephalomyelitis (EAE)

5 Experimental autoimmune encephalomyelitis (also called experimental allergic encephalomyelitis or EAE) is a demyelinating disease of the central nervous system that mimics multiple sclerosis (MS) (Zamvil, S.S., Steinman, L. *The T lymphocyte in experimental allergic encephalomyelitis*, Annu  
10 Rev Immunol 1990, 8, 579-621). It is induced in rats or mice by immunizing them with myelin antigens and various toxins in media such as Freund's adjuvant. (Bernard, C.C., Carnegie, P.R.), *Experimental autoimmune encephalomyelitis in mice: immunologic response to mouse spinal cord and myelin*  
15 *basic proteins*, J. Immunol. 1975 May; 114(5): 1537-40; Beck, F.W., Whitehouse, M.W., Pearson, C.M., *Improvements for consistently inducing experimental allergic encephalomyelitis (EAE) in rats: I. without using mycobacterium. II. inoculating encephalitogen into the ear*, Proc. Soc. Exp. Biol. Med. 1976 Mar;  
20 151(3): 615-22) and is used as a model for testing the efficacy of drugs in treating MS.

In this experiment the goal was to reduce experimental autoimmune encephalomyelitis (EAE) induced clinical signs in  
25 the Lewis rat model. Lewis (LEW) rats are highly susceptible to EAE induced with guinea pig spinal cord homogenate (GPSCH) emulsified in modified complete Freund's adjuvant (CFA). The earliest clinical signs begin 10-12 days after immunization and most rats recover by 18 to 20 days. Decreased signs of  
30 EAE in rats with test materials administered orally during the study is considered a protective effect set forth by the experimental design.

The animal were induced with the disease by subcutaneous injection of GPSCH emulsion into both hind paws on day 1. Initiation of scoring of rats for EAE clinical signs started on day 9. The treatment groups were blinded to the scorer. The 5 treatments or control treatments were started on day 1 and administered daily to day 22. Treatments were administered by oral gavage at a dose and frequency described in Table 2. There were ten rats in each group.

10 Table 2. Treatments

<b>Treatment group</b>	<b>Dose</b>	<b>Frequency</b>
Double Distilled Water (DDW) - control	5 ml / kg	Daily gavage starting on day 1
Wax-PVP nanoparticles - control	(21 mg particles)/ml 5 ml / kg	Daily gavage starting on day 1
Glatiramer Acetate solution	(2.5 mg GA)/ml 5 ml / kg	Daily gavage starting on day 1
Glatiramer Acetate - Wax - PVP nanoparticles	(2.5 mg GA bound to 21 mg particles)/ ml 5 ml / kg	Daily gavage starting on day 1

The animals were accessed daily for EAE clinical signs as described in Table 3.

15

Table 3. Evaluation of the EAE Clinical Signs.

Score	Clinical Signs	Description
0	Normal behavior	No clinical signs
1	Tail weakness	The tail is limp and droops.
2	Hind legs hypotonia and weakness.	Limb pareses, wobbly walk- when the rat walks the hind legs are unsteady or it drags one hind leg.
3	Hind legs paralysis, front legs normal	The rat can't move its hind legs and it drags them when it walks. Forelegs are normal
4	Hind legs paralysis, front legs weak	The rat can't move its hind legs and it drags them when it walks. Forelegs are weak
5	Full paralysis	The rat can't move all its four legs at all.
6	Moribund animals / Death.	

The following parameters were calculated:

5

Calculation of the incidence, mortality, onset and duration of disease

The number of sick animals in each group were assessed. The day of onset of the symptoms, the duration of days of the symptoms and the number of animals dying were noted and the percentages calculated.

10

Calculation of the mean maximal score (MMS)

The maximal scores of each of the animals in each group were summed. The mean maximal score of the group was calculated as follows:

15

$\Sigma$  Maximal score of each rat / number of rats in the group.

Calculation of the group mean score (GMS)

The scores of each of the animals in the group were summed and the mean score per day was calculated. The group mean  
5 score was calculated as follows:

$\Sigma$  Total score of each rat per day / number of rats in the group.

Results

10 Table 4 presents the data for disease incidence in the test animals.

Table 4. Incidence of EAE and Mortality

	Incidence		Mortality	
	Total		Total	
Group	N	%	N	%
DDW	10/10	100	1/10	10
GA	8/9	89	0/10	0
WAX-PVP	10/10	100	0/10	0
GA-WAX-PVP	9/10	90	0/10	0

15 The EAE was induced in all of the test animals in the water treatment control group and the wax-PVP nanoparticle vehicle control group while the disease was induced in eight of nine animals in the Glatiramer acetate oral solution group and  
20 nine of ten in the Glatiramer acetate nanoparticle treatment group. Only one animal died in the study.

Table 5 presents the duration and onset of the disease.

Table 5. EAE Duration and Onset

	Mean	Mean Onset
	Disease	
Group	Duration, days	days
DDW	4.6 $\pm$ 1.4	11.9 $\pm$ 1.0
GA	3.2 $\pm$ 1.6	13.0 $\pm$ 2.5
WAX-PVP	4.2 $\pm$ 0.8	11.8 $\pm$ 0.8
GA-WAX-PVP	3.4 $\pm$ 1.6	13.1 $\pm$ 2.3

The mean duration of the disease was shorter for the two Glatiramer acetate groups (3.2 and 3.4 days) than for the two control groups (4.6 and 4.2 days). The mean days to onset of disease symptoms was delayed in the two GA groups (13.0 and 13.1 days) when compared to the two vehicle groups (11.9 and 11.8 days). The Glatiramer acetate nanoparticle treatment group showed a slightly longer delay in onset but also a slightly longer duration of disease when compared to the oral solution Glatiramer acetate group. These differences were probably not significant.

Table 6 collects the mean daily scores for each of the groups and serves as a measure of disease severity.

Table 6. Daily Mean Score

days	Mean score			
	DDW	GA	Wax-PVP	GA-Wax-PVP
9	0.0	0.0	0.0	0.0
10	0.0	0.0	0.0	0.0
11	0.8	0.2	0.7	0.2
12	1.1	1.3	1.4	0.8
13	2.1	2.0	2.1	1.3
14	2.5	1.8	1.9	1.6
15	2.1	1.2	1.1	1.3
16	1.0	0.1	0.4	0.3
17	0.6	0.0	0.0	0.0
18	0.6	0.0	0.0	0.0
<b>AUC</b>	<b>10.8</b>	<b>6.6</b>	<b>7.6</b>	<b>5.5</b>

The symptoms started to manifest themselves on day 11 and peaked at day 13 or 14. The mean severity of the disease was highest with the treatment with the vehicles alone reaching 2.5 on day 14 with the water treatment and 2.1 at day 13 with the wax-PVP nanoparticle vehicle. Oral glatiramer acetate was somewhat better than the wax-PVP vehicle while the glatiramer acetate conjugated to the wax-PVP (GA-wax-PVP) gave considerably improved results reaching a maximum of only 1.6 on day 14. The area under the curve (AUC) shows that the GA-wax-PVP has a total severity of about half that of the water negative control and lower than the oral administration of GA not conjugated to the nanoparticles. The oral GA results are better than either vehicle treatment group. These results are shown graphically in Figure 1. The mean group scores are presented in Table 7.

Table 7. Mean Scores and % Inhibition

	Mean	Group	% of	
	Maximal	Mean	inhibition	
Group	Score	Score	vs. its placebo	vs. DDW
DDW	2.7 ± 1.3	1.08 ± 1.0		
GA	2.2 ± 1.1	0.67 ± 0.4	38%	38%
WAX-PVP	2.4 ± 1.0	0.76 ± 0.3		
GA-WAX-PVP	1.9 ± 0.9	0.55 ± 0.3	28%	49%

As in the previous tables the data presented here shows that mean score for each treatment group was better for the two  
 5 glatiramer acetate treatments (0.67 and 0.55) than for the two vehicle control treatments (1.08 and 0.76) with the glatiramer acetate nanoparticles showing the best results. The mean of the maximal disease severity in each group followed the same  
 10 trend with the glatiramer acetate nanoparticles having the lowest mean score (1.9). The glatiramer acetate oral solution showed a 38% inhibition of group mean score when compared to DDW, its control treatment. The glatiramer acetate nanoparticles showed a 28% inhibition in the mean group score compared to its vehicle as a control and a 49% inhibition  
 15 when compared to DDW as a control.

### Conclusion

The Example shows that the administration of an oral solution of glatiramer acetate or the oral administration of the  
 20 glatiramer acetate bound to nanoparticles inhibit the disease severity of EAE in rats. Treatment with the nanoparticle bound GA was shown to be more efficacious in most of the disease severity parameters.



Example 5 - Determination of Immunologic Activity of GA-Wax-PVP

The ability of GA-Wax-PVP to elicit an immune response with a similar cytokine pattern as glatiramer acetate solution was tested in an ex-vivo model in mice. The study was conducted over a period of 10 days. Mice were fed daily with GA reference standard (GA RS, 250  $\mu$ g), GA-Wax-PVP (amount equivalent to 250  $\mu$ g GA) or Wax-PVP as negative control (similar volume and weight of particles as GA-Wax-PVP). During the study period, subsets of animals in each treatment group were sacrificed on days 3, 6 and 10. Spleens were excised and primary cell cultures were prepared. The effect of the treatment was tested by in-vitro activation of splenocytes with GA RS. The response of the cells to the challenge is a measure of previous exposure to GA. Comparing the immune response of the mice fed GA-Wax-PVP to those fed GA RS gives a measure of the relative exposure to GA that each treatment provided. T-cell response was monitored by detection of cytokines secreted from activated cells by ELISA analysis. The levels of IL-2, TGF- $\beta$ , IL-4, IL-5, IL-10 and IFN- $\gamma$  were examined

Results

The levels of all the cytokines examined throughout the test period were similar for the mice fed GA RS and those fed GA-Wax-PVP. The results of IL-2 and TGF- $\beta$  measurements are shown below. Figure 2 shows that the Wax-PVP did not elicit any IL-2 response while the GA-Wax-PVP elicited a response that is similar in magnitude to the GA RS. Figure 3 also shows that the magnitude of the secretion of TGF- $\beta$  to the GA RS challenge is again of similar magnitude whether the mice were treated with GA RS or GA-Wax-PVP. The negative control also

elicited a response, which was smaller than the response elicited with the test substance, with this marker.

Conclusion

- 5 The GA-Wax-PVP particles are immunologically active and the cytokine pattern for GA-WAX-PVP and GA RS are similar.